pituitary axis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
James Windle notes that "prohibitions were enforced in Asian countries while the United States and Western Europe were routinely trading opium"; the "concept of prohibition being a distinctly American construct is, therefore, flawed". Collins concludes, "The United States was a key participant in the [International Drug Control System], albeit frequently an absent one, but hardly the sole force."
Exothermic chemical reactions in closed systems do not change mass, but do become less massive once the heat of reaction is removed, though this mass change is too small to measure with standard equipment. In nuclear reactions, the fraction of mass that may be removed as light or heat, i.e. binding energy, is often a much larger fraction of the system mass. It may thus be measured directly as a mass difference between rest masses of reactants and (cooled) products. This is because nuclear forces are comparatively stronger than the Coulombic forces associated with the interactions between electrons and protons that generate heat in chemistry.
Known instances of nuclear reactions, aside from producing energy, also produce nucleons and particles on readily observable ballistic trajectories. In support of their claim that nuclear reactions took place in their electrolytic cells, Fleischmann and Pons reported a neutron flux of 4,000 neutrons per second, as well as detection of tritium. The classical branching ratio for previously known fusion reactions that produce tritium would predict, with 1 watt of power, the production of 1012 neutrons per second, levels that would have been fatal to the researchers. In 2009, Mosier-Boss et al. reported what they called the first scientific report of highly energetic neutrons, using CR-39 plastic radiation detectors, but the claims cannot be validated without a quantitative analysis of neutrons. Several medium and heavy elements like calcium, titanium, chromium, manganese, iron, cobalt, copper and zinc have been reported as detected by several researchers, like Tadahiko Mizuno or George Miley. The report presented to the United States Department of Energy (DOE) in 2004 indicated that deuterium-loaded foils could be used to detect fusion reaction products and, although the reviewers found the evidence presented to them as inconclusive, they indicated that those experiments did not use state-of-the-art techniques.
Sources: en.wikipedia.org
== Effect on microorganisms == Low O2 and high CO2 concentrations in packages are effective in limiting the growth of Gram negative bacteria, molds and aerobic microorganisms, such as Pseudomonas spp. High O2 combined with high CO2 could have bacteriostatic and bactericidal effects by suppression of aerobes by high CO2 and anaerobes by high O2. CO2 has the ability to penetrate bacterial membrane and affect intracellular pH. Therefore, lag phase and generation time of spoilage microorganisms are increased resulting in shelf life extension of refrigerated foods. Since the growth of spoilage microorganisms are suppressed by MAP, the ability of the pathogens to grow is potentially increased. Microorganisms that can survive under low oxygen environment such as Campylobacter jejuni, Clostridium botulinum, E. coli, Salmonella, Listeria and Aeromonas hydrophila are of major concern for MA packaged products. Products may appear organoleptically acceptable due to the delayed growth of the spoilage microorganisms but might contain harmful pathogens. This risk can be minimized by use of additional hurdles such as temperature control (maintain temperature below 3 degrees C), lowering water activity (less than 0.92), reducing pH (below 4.5) or addition of preservatives such as nitrite to delay metabolic activity and growth of pathogens.
=== Nineteenth century === During the Victorian era, criminals and gangs started to form organizations which would collectively become London's criminal underworld. Criminal societies in the underworld started to develop their own ranks and groups which were sometimes called families and were often made up of lower-classes and operated on pick-pocketry, prostitution, forgery and counterfeiting, commercial burglary and even money laundering schemes. Unique also were the use of slang and argots used by Victorian criminal societies to distinguish each other, like those propagated by street gangs like the Peaky Blinders. One of the most infamous crime bosses in the Victorian underworld was Adam Worth, who was nicknamed "the Napoleon of the criminal world" or "the Napoleon of Crime" and became the inspiration behind the popular character of Professor Moriarty. Organized crime in the United States first came to prominence in the Old West and historians such as Brian J. Robb and Erin H. Turner traced the first organized crime syndicates to the Cochise Cowboy Gang and the Wild Bunch. The Cochise Cowboys, though loosely organized, were unique for their criminal operations in the Mexican border, in which they would steal and sell cattle as well smuggled contraband goods in between the countries. In the Old west there were other examples of gangs that operated in ways similar to an organized crime syndicate such as the Innocents gang, the Jim Miller gang, the Soapy Smith gang, the Belle Starr gang, and the Bob Dozier gang.
=== Clinical and clinicopathologic research and scholarship === Jennette and his associates have performed and published clinical and clinicopathologic studies, and recommendations for the management, diagnosis, and classification of kidney diseases. He was a member of consensus groups that published recommendations for pathologic diagnosis of kidney transplant rejection, focal segmental glomerulosclerosis, IgA nephropathy, membranoproliferative glomerulonephritis, C1q nephropathy, membranous nephropathy, lupus nephritis, and ANCA glomerulonephritis. In 1994 and 2012, Jennette and his associate Falk led two international consensus conferences that standardized the names and pathologic features of different forms of vascular inflammation (vasculitis). Jennette and Falk established the Glomerular Disease Collaborative Network (GDCN) in 1985 to promote collaborative research on glomerular disease among UNC faculty in nephrology and nephropathology, along with community practice nephrologists who refer kidney biopsies to UNC for diagnosis. Clinical and clinicopathologic research projects have utilized GDCN resources, including the article published by Jennette and Falk in The New England Journal of Medicine in 1988, which reported the discovery that one major antigen target of ANCA is myeloperoxidase (MPO-ANCA) and clarified the diverse clinical and pathologic spectrum of ANCA disease, using data and samples obtained through the GDCN. In 1990, they documented that the other major antigen specificity of ANCA is proteinase 3 (PR3-ANCA).
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.